Hepatocellular carcinoma as a leading cause of cancer-related deaths in Japanese type 2 diabetes mellitus patients.
Aged
Carcinoma, Hepatocellular
/ epidemiology
Cohort Studies
Cross-Sectional Studies
Diabetes Mellitus, Type 2
/ epidemiology
Female
Follow-Up Studies
Hepatitis B Surface Antigens
/ blood
Humans
Japan
/ epidemiology
Liver Neoplasms
/ epidemiology
Longitudinal Studies
Male
Middle Aged
Prospective Studies
Hepatocellular carcinoma
Mortality risk
Platelet count
Type 2 diabetes mellitus
Journal
Journal of gastroenterology
ISSN: 1435-5922
Titre abrégé: J Gastroenterol
Pays: Japan
ID NLM: 9430794
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
16
12
2017
accepted:
30
06
2018
pubmed:
15
7
2018
medline:
18
12
2019
entrez:
15
7
2018
Statut:
ppublish
Résumé
We reported a cross-sectional study on causes of liver injury in Japanese type 2 diabetes mellitus (T2D) patients (JG 2013). We assessed overall and cause-specific mortality risk during follow-up of patients enrolled in JG 2013. This was a longitudinal, multicenter cohort study. Of the 5642 Japanese T2D patients who visited T2D clinics of nine hospitals in the original study, 3,999 patients were followed up for an average of 4.5 years. Expected deaths in T2D patients were estimated using age-specific mortality rates in the general population (GP) of Japan. Standardized mortality ratios (SMRs) were calculated to compare mortality between T2D patients and GP. All-cancer mortality was significantly higher in T2D patients than in the GP [SMR 1.58, 95% confidence interval (CI) 1.33-1.87]. Among malignancies, hepatocellular carcinoma (HCC) conferred the highest mortality risk in T2D patients (SMR 3.57, 95% CI 2.41-5.10). HCC-associated mortality risk in T2D patients remained significantly high (SMR 2.56, 95% CI 1.64-3.97) after adjusting for high positivity rates of hepatitis B surface antigen (1.7%) and anti-hepatitis C virus (5.3%). In T2D patients with platelet counts < 200 × 10 HCC-associated mortality risk was the highest among all cancers in Japanese T2D patients. Regular follow-up may be important for T2D patients with platelet counts < 200 × 10
Sections du résumé
BACKGROUND
BACKGROUND
We reported a cross-sectional study on causes of liver injury in Japanese type 2 diabetes mellitus (T2D) patients (JG 2013). We assessed overall and cause-specific mortality risk during follow-up of patients enrolled in JG 2013.
METHODS
METHODS
This was a longitudinal, multicenter cohort study. Of the 5642 Japanese T2D patients who visited T2D clinics of nine hospitals in the original study, 3,999 patients were followed up for an average of 4.5 years. Expected deaths in T2D patients were estimated using age-specific mortality rates in the general population (GP) of Japan. Standardized mortality ratios (SMRs) were calculated to compare mortality between T2D patients and GP.
RESULTS
RESULTS
All-cancer mortality was significantly higher in T2D patients than in the GP [SMR 1.58, 95% confidence interval (CI) 1.33-1.87]. Among malignancies, hepatocellular carcinoma (HCC) conferred the highest mortality risk in T2D patients (SMR 3.57, 95% CI 2.41-5.10). HCC-associated mortality risk in T2D patients remained significantly high (SMR 2.56, 95% CI 1.64-3.97) after adjusting for high positivity rates of hepatitis B surface antigen (1.7%) and anti-hepatitis C virus (5.3%). In T2D patients with platelet counts < 200 × 10
CONCLUSIONS
CONCLUSIONS
HCC-associated mortality risk was the highest among all cancers in Japanese T2D patients. Regular follow-up may be important for T2D patients with platelet counts < 200 × 10
Identifiants
pubmed: 30006904
doi: 10.1007/s00535-018-1494-7
pii: 10.1007/s00535-018-1494-7
doi:
Substances chimiques
Hepatitis B Surface Antigens
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
64-77Subventions
Organisme : Grant-in-Aid from the Ministry of Health, Labour and Welfare, Japan
ID : H20-Hepatitis-general-008
Organisme : Japan Agency for Medical Research and Development
ID : the Research Program on Hepatitis
Références
Hotta N, Nakamura J, Iwamoto Y, et al. Causes of death in Japanese diabetics: a questionnaire survey of 18,385 diabetics over a 10-year period. J Diabetes Investig. 2010;1:66–76.
doi: 10.1111/j.2040-1124.2010.00019.x
pubmed: 24843411
pmcid: 4020680
Nakamura J, Kamiya H, Haneda M, et al. Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001–2010: report of Committee on Causes of Death in Diabetes Mellitus. Diabetol Int. 2017;8:117–36.
doi: 10.1007/s13340-017-0313-3
pubmed: 30603315
pmcid: 6224959
Vital Statistics Japan from Ministry of Health, Labour and Welfare. http://www.e-stat.go.jp/SG1/estat/List.do?lid=000001137965 . Accessed 30 Oct 2017.
Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan. http://ganjoho.jp/reg_stat/statistics/dl/index.html . Accessed 30 Oct 2017.
Tateishi R, Okanoue T, Fujiwara N, et al. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. J Gastroenterol. 2015;50:350–60.
doi: 10.1007/s00535-014-0973-8
pubmed: 24929638
Shima T, Uto H, Ueki K, et al. Clinicopathological features of liver injury in patients with type 2 diabetes mellitus and comparative study of histologically proven nonalcoholic fatty liver diseases with or without type 2 diabetes mellitus. J Gastroenterol. 2012;48:515–25.
doi: 10.1007/s00535-012-0653-5
pubmed: 22911170
Diabetes C, Complications Trial/Epidemiology of Diabetes I, Complications Study Research G. Mortality in type 1 diabetes in the DCCT/EDIC versus the general population. Diabetes Care. 2016;39:1378–83.
Atkinson EJ CC, Pedersen RA, Therneau TM. Poisson models for person-years and expected rates. Technical report #81. http://www.mayo.edu/research/documents/biostat-81pdf/doc-10026981 . Accessed 30 Oct 2017.
Breslow NE, Day NE. Statistical methods in cancer research. Volume II—the design and analysis of cohort studies. IARC Scientific Publications No. 82. Oxford: Oxford University Press; 1987.
Yoneda M, Fujii H, Sumida Y, et al. Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. J Gastroenterol. 2011;46:1300–6.
doi: 10.1007/s00535-011-0436-4
pubmed: 21750883
Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1104–12.
doi: 10.1016/j.cgh.2009.05.033
pubmed: 19523535
pmcid: 3079239
Peleg AY, Weerarathna T, McCarthy JS, et al. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev. 2007;23:3–13.
doi: 10.1002/dmrr.682
pubmed: 16960917
Noto H, Osame K, Sasazuki T, et al. Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan. J Diabetes Complications. 2010;24:345–53.
doi: 10.1016/j.jdiacomp.2010.06.004
pubmed: 20656522
Noto H, Tsujimoto T, Sasazuki T, et al. Significantly increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Endocr Pract. 2011;17:616–28.
doi: 10.4158/EP10357.RA
pubmed: 21454235
Sasazuki S, Charvat H, Hara A, et al. Diabetes mellitus and cancer risk: pooled analysis of eight cohort studies in Japan. Cancer Sci. 2013;104:1499–507.
doi: 10.1111/cas.12241
pubmed: 23889822
Inoue M, Iwasaki M, Otani T, et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med. 2006;166:1871–7.
doi: 10.1001/archinte.166.17.1871
Tanaka K, Tsuji I, Tamakoshi A, et al. Diabetes mellitus and liver cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol. 2014;44:986–99.
doi: 10.1093/jjco/hyu108
pubmed: 25104789
Kasuga M, Ueki K, Tajima N, et al. Report of the Japan Diabetes Society/Japanese Cancer Association Joint Committee on Diabetes and Cancer. Cancer Sci. 2013;104:965–76.
doi: 10.1111/cas.12203
pubmed: 23879470
Wang C, Wang X, Gong G, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2012;130:1639–48.
doi: 10.1002/ijc.26165
pubmed: 21544812
Chen Y, Wu F, Saito E, et al. Association between type 2 diabetes and risk of cancer mortality: a pooled analysis of over 771,000 individuals in the Asia Cohort Consortium. Diabetologia. 2017;60:1022–32.
doi: 10.1007/s00125-017-4229-z
pubmed: 28265721
pmcid: 5632944
Kato M, Noda M, Mizoue T, et al. Diagnosed diabetes and premature death among middle-aged Japanese: results from a large-scale population-based cohort study in Japan (JPHC study). BMJ Open. 2015;5:e007736.
doi: 10.1136/bmjopen-2015-007736
pubmed: 25941187
pmcid: 4420968
Sasaki A, Horiuchi N, Hasegawa K, et al. Causes of death in Japanese diabetics. A 20-year study of death certificates. J Chronic Dis. 1985;38:655–61.
doi: 10.1016/0021-9681(85)90019-0
pubmed: 4019702
Koh WP, Wang R, Jin A, et al. Diabetes mellitus and risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. Br J Cancer. 2013;108:1182–8.
doi: 10.1038/bjc.2013.25
pubmed: 23370206
pmcid: 3619062
Loomba R, Abraham M, Unalp A, et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012;56:943–51.
doi: 10.1002/hep.25772
pubmed: 22505194
pmcid: 3407289
Porepa L, Ray JG, Sanchez-Romeu P, et al. Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. CMAJ. 2010;182:E526–31.
doi: 10.1503/cmaj.092144
pubmed: 20566726
pmcid: 2917963
Nakahara T, Hyogo H, Yoneda M, et al. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol. 2014;49:1477–84.
doi: 10.1007/s00535-013-0911-1
pubmed: 24277052
White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10(1342–59):e2.
Chen CL, Yang HI, Yang WS, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008;135:111–21.
doi: 10.1053/j.gastro.2008.03.073
pubmed: 18505690
Chen J, Han Y, Xu C, et al. Effect of type 2 diabetes mellitus on the risk for hepatocellular carcinoma in chronic liver diseases: a meta-analysis of cohort studies. Eur J Cancer Prev. 2015;24:89–99.
doi: 10.1097/CEJ.0000000000000038
pubmed: 24809655
Yoshimura K, Okanoue T, Ebise H, et al. Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining. Hepatology. 2016;63:462–73.
doi: 10.1002/hep.28226
pubmed: 26390046
Okanoue T, Ebise H, Kai T, et al. A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis. J Gastroenterol. 2018;53:129–39.
doi: 10.1007/s00535-017-1355-9
pubmed: 28589339
Kawamura Y, Arase Y, Ikeda K, et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol. 2012;107:253–61.
doi: 10.1038/ajg.2011.327
pubmed: 22008893
Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33:1674–85.
doi: 10.2337/dc10-0666
pubmed: 20587728
pmcid: 20587728
Onitilo AA, Engel JM, Glurich I, et al. Diabetes and cancer II: role of diabetes medications and influence of shared risk factors. Cancer Causes Control. 2012;23:991–1008.
doi: 10.1007/s10552-012-9971-4
pubmed: 22527174
pmcid: 4138811
Walker JJ, Johnson JA, Wild SH. Diabetes treatments and cancer risk: the importance of considering aspects of drug exposure. Lancet Diabetes Endocrinol. 2013;1:132–9.
doi: 10.1016/S2213-8587(13)70028-7
pubmed: 24622319
Kawaguchi T, Kohjima M, Ichikawa T, et al. The morbidity and associated risk factors of cancer in chronic liver disease patients with diabetes mellitus: a multicenter field survey. J Gastroenterol. 2015;50:333–41.
doi: 10.1007/s00535-014-0968-5
pubmed: 24912965
Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia. 2011;54:25–31.
doi: 10.1007/s00125-010-1933-3
pubmed: 20959956
Goto A, Noto H, Noda M, et al. Report of the Japan Diabetes Society (JDS)/Japanese Cancer Association (JCA) Joint Committee on Diabetes and Cancer, second report. Diabetol Int. 2016;7:12–5.
doi: 10.1007/s13340-016-0257-z
pubmed: 30603237
pmcid: 6224904